The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

Cancer Recurrence, Clinical Trials, High Risk Prostate Cancer, Intermediate Risk Prostate Cancer, Low Risk Prostate Cancer, Metastatic Castration Resistant Prostate Cancer (MCRPC), Metastatic Castration Sensitive Prostate Cancer (MCSPC), Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05010200
Phase: Phase 1
Trial Summary: This proof of concept study is designed to test the safety and tolerability of PGV001-based personalized multi-peptide vaccines in combination with CDX-301 in subjects with a histo – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Ashutosh Kumar Tewari
Acronym: PGV-Prostate

Pin It on Pinterest